NASDAQ, TSX: NVCN VANCOUVER, Feb. 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares")...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 27, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 26, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has commenced a proposed underwritten public offering (the "Offering") of common shares of the Company (the "Common Shares"). H.C. Wainwright...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 22, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) wishes to advise that it has filed the following amendments, which documents are publicly available on SEDAR at www.sedar.com: unaudited amended and restated condensed interim...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 21, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, Feb. 20, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina,...
Read MoreNASDAQ, TSX: NVCN Second U.S. patient successfully undergoes Reducer procedure under compassionate use VANCOUVER, Feb. 11, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally...
Read More